Profile photo Sjoerd Elias

Sjoerd Elias

Associate Professor

Strategic program(s):

Biography

I obtained my MSc in Clinical Epidemiology at the Netherlands Institute for Health Sciences (2002), and my PhD at Utrecht University (2003). Following graduation from Medical School in 2005 I worked as a resident in radiology (Gelre Ziekenhuizen Apeldoorn, the Netherlands, 2006-2007). A personal Dutch Cancer Society Research Fellowship (2009-2013) enabled me to work as a visiting scientist at the Molecular Imaging Program at Stanford (professor SS Gambhir), the Department of Radiology and Biomedical Imaging at the University of California San Francisco (professor NM Hylton), and the Department of Molecular Pathology at the Netherlands Cancer Institute (professor LJ van't Veer). Since 2008, I work as a Clinical Epidemiologist in the research programs Cancer and Methodology at the Julius Center for Health Sciences and Primary Care, since 2018 as Associate Professor. Furthermore, I have more than ten years of experience in teaching and coordinating courses in clinical epidemiology, both nationally as well as internationally. Since 2020 I am coordinator of the PhD program Clinical and Translational Oncology, and since 2021 I am coordinator of the Research Program Cancer and management team member of the Epidemiology department of the Julius Center, as well as board member of the UMC Utrecht Strategic Program Cancer.

Interests and Focus

My main research focus is on the clinical evaluation and translation of biomarkers, particularly for cancer classification (i.e. diagnostic, prognostic, and predictive markers). These markers include emerging imaging technologies such as molecular imaging, omics-based tests, and organoids. I have both experience in preclinical research as well as applied clinical science, and have expertise and experience in the design and analysis of studies spanning all (translation) phases of biomarker development, as well as treatment studies (from phase I through phase III).

Strategic program(s):

Contact

Research groups

Decision support systems for precision care in translational cancer-imaging

Research aim

To develop, validate and implement decision support systems based on imaging for the diagnosis, prognosis and triaging of oncology patients
Go to group

Julius Center Research Program Cancer

Research aim

Our mission is to drive impactful innovation for cancer prevention, diagnosis, prognosis, treatment, and care through interdisciplinary research, fostering collaboration among researchers across disciplines within the Julius Center and beyond.
Go to group

Early (T1-T2) colorectal cancers

Research aim

To minimize the impact of treatment for early (T1-T2) colorectal cancers, while preserving the high survival rates, achieve the highest quality of life for patients, and lower the healthcare costs.
Go to group

Recent publications

Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer Jorianne Boers, Bertha Eisses, Mieke C. Zwager, Jasper J.L. van Geel, Frederike Bensch, Erik F.J. de Vries, Geke A.P. Hospers, Andor W.J.M. Glaudemans, Adrienne H. Brouwers, Martijn A.M. den Dekker, Sjoerd G. Elias, Evelien J.M. Kuip, Carla M.L. van Herpen, Agnes Jager, Astrid A.M. van der Veldt, Daniela E. Oprea-Lager, Elisabeth G.E. de Vries, Bert van der Vegt, Willemien C. Menke-van der Houven van Oordt, Carolina P. Schröder,
Diagnostics, 2024, vol. 14
Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer Bertha Eisses, Jasper J.L. van Geel, Adrienne H. Brouwers, Frederike Bensch, Sjoerd G. Elias, Evelien J.M. Kuip, Agnes Jager, Bert van der Vegt, Marjolijn N. Lub-de Hooge, Jasper Emmering, Anne I.J. Arens, Gerben J.C. Zwezerijnen, Daniëlle J. Vugts, C. Willemien Menke-van der Houven van Oordt, Elisabeth G.E. de Vries, Carolina P. Schröder
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2024, vol. 65, p.1540-1547
The prognostic potential of mammographic growth rate of invasive breast cancer in the Nijmegen breast cancer screening cohort Jim Peters, Jos A.A.M. van Dijck, Sjoerd G. Elias, Johannes D.M. Otten, Mireille J.M. Broeders,
Journal of Medical Screening, 2024, vol. 31, p.166-175
First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases Paulien Rauwerdink, Vincent C.J. van de Vlasakker, Emma C.E. Wassenaar, Koen P. Rovers, Maartje Los, Karin H. Herbschleb, Geert Jan M. Creemers, Annemarie M.J. Thijs, Mihaela G. Raicu, Clément J.R. Huysentruyt, Erik J.R.J. van der Hoeven, Joost Nederend, Rifka Y.M. Peeters, Maarten J. Deenen, Sjoerd G. Elias, Remond J.A. Fijneman, Alexander Constantinides, Onno Kranenburg, Pim W.A. Burger, Simon W. Nienhuijs, René J. Wiezer, Robin J. Lurvink, Ignace H.J.T. de Hingh, Djamila Boerma
European Journal of Surgical Oncology, 2024, vol. 50
Predicting response to neoadjuvant chemotherapy with liquid biopsies and multiparametric MRI in patients with breast cancer L. M. Janssen, M. H.A. Janse, B. B.L. Penning de Vries, B. H.M. van der Velden, E. J.M. Wolters-van der Ben, S. M. van den Bosch, A. Sartori, C. Jovelet, M. J. Agterof, D. Ten Bokkel Huinink, E. W. Bouman-Wammes, P. J. van Diest, E. van der Wall, S. G. Elias, K. G.A. Gilhuijs
npj Breast Cancer, 2024, vol. 10
A prediction model for response to immune checkpoint inhibition in advanced melanoma Isabella A J van Duin, Rik J Verheijden, Paul J van Diest, Willeke A M Blokx, Mary-Ann El-Sharouni, Joost J C Verhoeff, Tim Leiner, Alfonsus J M van den Eertwegh, Jan Willem B de Groot, Olivier J van Not, Maureen J B Aarts, Franchette W P J van den Berkmortel, Christian U Blank, John B A G Haanen, Geke A P Hospers, Djura Piersma, Rozemarijn S van Rijn, Astrid A M van der Veldt, Gerard Vreugdenhil, Michel W J M Wouters, Marion A M Stevense-den Boer, Marye J Boers-Sonderen, Ellen Kapiteijn, Karijn P M Suijkerbuijk, Sjoerd G Elias
International Journal of Cancer, 2024, vol. 154, p.1760-1771

External positions

Lid KWF beoordelingscommissie Exploratie: beslissingen rondom honoreren subsidieaanvragen - Inzet eigen wetenschappelijke expertise, inzicht in wat speelt in eigen onderzoeksgebied - KWF Kankerbestrijding

Lid KWF beoordelingscommissie Exploratie: beslissingen rondom honoreren subsidieaanvragen - Inzet eigen wetenschappelijke expertise, inzicht in wat speelt in eigen onderzoeksgebied - KWF Kankerbestrijding